Article Text

PDF
Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial
  1. H Schmidt1,
  2. W Kern2,
  3. R Giese3,
  4. M Hallschmid4,
  5. A Enders3
  1. 1
    Department of Paediatric Endocrinology and Medical Genetics, Dr. von Hauner Children’s Hospital, University of Munich, Lindwurmstr. 4, 80337 Munich/Germany
  2. 2
    Departments of Internal Medicine I, University of Lübeck, Ratzeburger Alle 160, Lübeck/Germany
  3. 3
    Department of Paediatric Neurology, Dr. von Hauner Children’s Hospital, University of Munich, Lindwurmstr. 4, 80337 Munich, Germany
  4. 4
    Departments of Neuroendocrinology, University of Lübeck, Ratzeburger Alle 160, Lübeck/Germany
  1. Professor H Schmidt, Dr von Hauner Children’s Hospital, University of Munich, Lindwurmstr. 4, 80337 Munich, Germany; heinrich.schmidt{at}med.uni-muenchen.de

Abstract

Background: The 22q13 deletion syndrome (Phelan–McDermid syndrome) is characterised by a global developmental delay, absent or delayed speech, generalised hypotonia, autistic behaviour and characteristic phenotypic features. Intranasal insulin has been shown to improve declarative memory in healthy adult subjects and in patients with Alzheimer disease.

Aims: To assess if intranasal insulin is also able to improve the developmental delay in children with 22q13 deletion syndrome.

Methods: We performed exploratory clinical trials in six children with 22q13 deletion syndrome who received intranasal insulin over a period of 1 year. Short-term (during the first 6 weeks) and long-term effects (after 12 months of treatment) on motor skills, cognitive functions, or autonomous functions, speech and communication, emotional state, social behaviour, behavioural disorders, independence in daily living and education were assessed.

Results: The children showed marked short-term improvements in gross and fine motor activities, cognitive functions and educational level. Positive long-term effects were found for fine and gross motor activities, nonverbal communication, cognitive functions and autonomy. Possible side effects were found in one patient who displayed changes in balance, extreme sensitivity to touch and general loss of interest. One patient complained of intermittent nose bleeding.

Conclusions: We conclude that long-term administration of intranasal insulin may benefit motor development, cognitive functions and spontaneous activity in children with 22q13 deletion syndrome.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.